Copyright
©The Author(s) 2023.
World J Gastroenterol. Jan 14, 2023; 29(2): 390-409
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.390
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.390
Figure 1 Therapeutic regimens recommended by Maastricht V/Florence consensus report as first-line and second-line treatment.
PPI: Proton pump inhibitor.
Figure 2 Preferred Reporting Items for Systematic reviews and Meta-Analyzes flow diagram.
H. pylori: Helicobacter pylori.
Figure 3 Third-line triple therapy eradication rates.
A: Triple therapy as third line (per protocol); B: Triple therapy as third line (intention to treat).
Figure 4 Triple therapy eradication rates as rescue treatment.
A: Triple therapy as rescue treatment (per protocol); B: Triple therapy as rescue treatment (intention to treat).
Figure 5 Third-line quadruple therapy eradication rates.
A: Quadruple therapy as third-line treatment (per protocol); B: Quadruple therapy as third-line treatment (intention to treat). BQT: Bismuth quadruple therapy; N-BQT: Non-bismuth quadruple therapy.
Figure 6 Quadruple therapy eradication rates as rescue treatment.
A: Quadruple therapy as rescue treatment (per protocol); B: Quadruple therapy as rescue treatment (intention to treat). BQT: Bismuth quadruple therapy; N-BQT: Non-bismuth quadruple therapy.
Figure 7 Recommendation diagram.
- Citation: de Moraes Andrade PV, Monteiro YM, Chehter EZ. Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review. World J Gastroenterol 2023; 29(2): 390-409
- URL: https://www.wjgnet.com/1007-9327/full/v29/i2/390.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i2.390